Document Detail


Ventricular tachycardia in "end stage" hypertrophic cardiomyopathy: a role of dronedarone.
MedLine Citation:
PMID:  23147440     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Hypertrophic cardiomyopathy (HCM) occurs in 1 in every 500 individuals. It represents the most common cause of sudden cardiac death in those under the age of twenty-five. 3-5% patients with HCM go on to develop the dilated, hypokinetic end stage (ES) HCM with systolic failure. They have a higher incidence of heart failure, sudden deaths and defibrillator shocks. To the best of our knowledge this is first report of successful use of dronedarone for suppression of VT associated with ES HCM.
Authors:
S Nanda; V Levin; M W Martinez
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  60     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  637-42     Citation Subset:  IM    
Affiliation:
Division of Cardiovascular Medicine, Lehigh Valley Health Network, Allentown, PA, USA - Matthew_W.Martinez@lvhn.org.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term patient benefit with biodegradable polymer biolimus eluting stent.
Next Document:  Extracranial internal carotid artery stenting in Moya-Moya syndrome: a case report.